CHMP recommends EU approval for NewAmsterdam’s obicetrapib therapies, paving potential market entry
Executive summary: The CHMP adopted a positive opinion recommending EU marketing authorization for NewAmsterdam Pharma’s obicetrapib monotherapy (Ubeslo) and its obicetrapib/ezetimibe fixed‑dose combination (Evlarco), based on positive Phase 3 trial data. Approval would introduce a novel CETP inhibitor to the EU market, offering a new LDL‑C‑lowering option that could capture share from statins and PCSK9 inhibitors and generate fresh revenue for NewAmsterdam and Menarini.
Who is involved: NewAmsterdam Pharma, Menarini Group, the Committee for Medicinal Products for Human Use (CHMP) of the EMA, and the European Commission.
Likely next: The European Commission is expected to issue its final decision by late September 2026 (within 60 days of the CHMP opinion); if approved, launch in key EU markets such as Germany and Italy is planned for early 2027, followed by pricing and reimbursement negotiations.
The CHMP issued a positive opinion based on positive Phase 3 BROADWAY, BROOKLYN and TANDEM data, recommending marketing authorization for obicetrapib monotherapy (Ubeslo) and its fixed‑dose combination with ezetimibe (Evlarco). This step moves the novel CETP inhibitor closer to patients in the European Union, where it would compete with existing LDL‑lowering therapies such as statins and PCSK9 inhibitors. The final authorization decision now lies with the European Commission, which has approximately 60 days to act, with a decision expected by late September 2026.
What's next — scenarios
Regulatory Smooth Sailing (Base Case) (65%)
NewAmsterdam secures EU market entry as expected, establishing a new competitive foothold in the lipid-lowering segment.
- European Commission formal approval of Ubeslo/Evlarco
- Positive pricing/reimbursement negotiations in key EU markets
Delayed or Conditional Approval (Downside) (25%)
Stalled commercialization timeline creates cash flow drag and delays competitive entry against PCSK9 inhibitors.
- EC request for additional safety data
- CHMP recommendation updated with restrictive labeling restrictions
Market Dominance Acceleration (Upside) (10%)
Rapid uptake driven by superior efficacy over current standard of care, leading to early partnership scaling with Menarini.
- Early positive real-world evidence from Phase 3 sub-groups
- Fast-track reimbursement status in Germany or France
Regulatory Rejection (Tail Risk) (1%)
Complete loss of anticipated EU revenue stream for the obicetrapib franchise.
- EC refusal of marketing authorization
- Significant undisclosed safety signal in post-CHMP review
What to watch
- European Commission formal decision announcement (by late September 2026)
- NewAmsterdam investor relations updates on EMA communication
- Comparative efficacy data publications regarding LDL-C lowering vs statins (Next 90 days)
- Menarini Group strategic commentary on EU commercial rollout plans
Timeline
- — NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib) (PR Newswire)
- — NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe) (PR Newswire)
- — NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo® (PR Newswire)
- — NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (PR Newswire)
Analysis — what this means
Likely next events
- European Commission expected to issue final decision on Ubeslo/Evlarco authorization by Q4 2026 (approximately 60 days after the CHMP opinion, i.e., late September 2026)
- If approved, NewAmsterdam plans to launch Ubeslo in Germany and Italy in Q1 2027
- Menarini intends to seek reimbursement agreements with major EU health authorities by mid‑2027
Sectors affected
- Pharmaceuticals
- Lipid‑lowering therapy market
- Cardiovascular drugs
Regulatory implications
- CHMP positive opinion triggers the centralized EU authorization procedure; the European Commission has 60 days to adopt a final decision (expected by late September 2026)
- Post‑approval, the companies must submit a Phase IV safety study and comply with EU pharmacovigilance and post‑authorization safety study (PASS) requirements
- Once authorized, the drug will be subject to EU pricing and reimbursement negotiations under each member state’s health technology assessment (HTA) process
Historical parallels
- CHMP positive opinion for bempedoic acid (Nexletol) in July 2020 preceded EU marketing authorization in January 2021
- CHMP positive opinion for inclisiran (Leqvio) in October 2020 preceded EU approval in November 2020
- CHMP positive opinion for evolocumab (Repatha) in August 2015 preceded EU authorization in the same month
Key entities
Sources
- NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib) — PR Newswire
- NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo® — PR Newswire
- NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe) — PR Newswire
- NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) — PR Newswire